RT Journal Article
T1 In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain
A1 Suárez-García, Inés
A1 Perales-Fraile, Isabel
A1 González-García, Andrés
A1 Muñoz-Blanco, Arturo
A1 Manzano, Luis
A1 Fabregate, Martín
A1 Díez-Manglano, Jesús
A1 Fonseca Aizpuru, Eva
A1 Arnalich Fernández, Francisco
A1 García García, Alejandra
A1 Gómez-Huelgas, Ricardo
A1 Ramos-Rincón, José-Manuel
K1 COVID-19
K1 Spain
K1 Odds ratio
K1 Myocarditis
K1 Hospital mortality
K1 Multiple organ failure
K1 Heart failure
K1 Hematologic neoplasms
K1 Prognosis
K1 Immunosuppression
K1 España
K1 Oportunidad relativa
K1 Miocarditis
K1 Mortalidad hospitalaria
K1 Insuficiencia multiorgánica
K1 Insuficiencia cardíaca
K1 Neoplasias hematológicas
K1 Diagnóstico
K1 Inmunosupresión
AB BackgroundWhether immunosuppressed (IS) patients have a worse prognosis of COVID-19 compared to non-IS patients is not known. The aim of this study was to evaluate the clinical characteristics and outcome of IS patients hospitalized with COVID-19 compared to non-IS patients.MethodsWe designed a retrospective cohort study. We included all patients hospitalized with laboratory-confirmed COVID-19 from the SEMI-COVID-19 Registry, a large multicentre national cohort in Spain, from March 27th until June 19th, 2020. We used multivariable logistic regression to assess the adjusted odds ratios (aOR) of in-hospital death among IS compared to non-IS patients.ResultsAmong 13 206 included patients, 2 111 (16.0%) were IS. A total of 166 (1.3%) patients had solid organ (SO) transplant, 1081 (8.2%) had SO neoplasia, 332 (2.5%) had hematologic neoplasia, and 570 (4.3%), 183 (1.4%) and 394 (3.0%) were receiving systemic steroids, biological treatments, and immunosuppressors, respectively. Compared to non-IS patients, the aOR (95% CI) for in-hospital death was 1.60 (1.43–1.79) for all IS patients, 1.39 (1.18–1.63) for patients with SO cancer, 2.31 (1.76–3.03) for patients with haematological cancer and 3.12 (2.23–4.36) for patients with SO transplant. The aOR (95% CI) for death for patients who were receiving systemic steroids, biological treatments and immunosuppressors compared to non-IS patients were 2.16 (1.80–2.61), 1.97 (1.33–2.91) and 2.06 (1.64–2.60), respectively. IS patients had a higher odds than non-IS patients of in-hospital acute respiratory distress syndrome, heart failure, myocarditis, thromboembolic disease and multiorgan failure.ConclusionsIS patients hospitalized with COVID-19 have a higher odds of in-hospital complications and death compared to non-IS patients.
PB Public Library of Science
YR 2021
FD 2021-08-03
LK http://hdl.handle.net/10668/4570
UL http://hdl.handle.net/10668/4570
LA en
NO Suárez-García I, Perales-Fraile I, González-García A, Muñoz-Blanco A, Manzano L, Fabregate M, et al. In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain. PLoS One. 2021 Aug 3;16(8):e0255524
DS RISalud
RD Aug 8, 2025